A new way: Foundation lines up generic heart drug for multiple sclerosis trial
-
Kees P
Is al oud nieuws:
Is al oud nieuws:
[QUOTE=Robbie;949102][url]http://www.bizjournals.com/sanfrancisco ... r-mrf.html[/url][/QUOTE]
Is (helaas)al redelijk oud nieuws (2011):
[url]http://www.gezondheidsplein.nl/nieuws/1 ... ujhgrQ1jmE[/url]
[QUOTE=Robbie;949102][url]http://www.bizjournals.com/sanfrancisco ... r-mrf.html[/url][/QUOTE]
Is (helaas)al redelijk oud nieuws (2011):
[url]http://www.gezondheidsplein.nl/nieuws/1 ... ujhgrQ1jmE[/url]
-
Robbie
Nee, nee volgende fase is in aantocht (ik krijg direct nieuws van MRF)
[QUOTE] [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="][IMG]http://ih.constantcontact.com/fs120/101 ... mg/282.jpg[/IMG][/URL]
Dear Robert,
We are thrilled to announce that the MRF is partnering with the National Institutes of Health (NIH) to conduct a clinical trial on a new potential therapeutic that may protect and repair myelin in multiple sclerosis (MS) patients.
This clinical trial marks a major milestone in our quest to provide next-generation treatments to MS patients by 2019.
Unlike current MS therapies, which all suppress the immune system, this drug (which we call MRF-008) may help protect the brain's myelin-producing cells from damage.
The MRF has launched an online [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="]fundraising campaign[/URL] to help cover a portion of the clinical trial costs. Our goal is to raise $200,000 online by June. [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="]Click here to make your online gift today![/URL]
Please join our campaign and help support this trial and advance new treatments for MS patients. To make a gift of securities or a fund transfer, contact one of our professional Major Gift Officers at (408) 871-2410. Virginia, Gary, Helen or Patrick would be happy to help you with your contribution.
You can also help by forwarding this email to your friends, co-workers and family members.
All my best,
[IMG]http://ih.constantcontact.com/fs120/101 ... mg/285.png[/IMG]
Virginia Saifer
Chief Development Officer
Myelin Repair Foundation
[/QUOTE]
[QUOTE] [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="][IMG]http://ih.constantcontact.com/fs120/101 ... mg/282.jpg[/IMG][/URL]
Dear Robert,
We are thrilled to announce that the MRF is partnering with the National Institutes of Health (NIH) to conduct a clinical trial on a new potential therapeutic that may protect and repair myelin in multiple sclerosis (MS) patients.
This clinical trial marks a major milestone in our quest to provide next-generation treatments to MS patients by 2019.
Unlike current MS therapies, which all suppress the immune system, this drug (which we call MRF-008) may help protect the brain's myelin-producing cells from damage.
The MRF has launched an online [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="]fundraising campaign[/URL] to help cover a portion of the clinical trial costs. Our goal is to raise $200,000 online by June. [URL="http://r20.rs6.net/tn.jsp?f=001349Q9oPT ... IRb2RNVA=="]Click here to make your online gift today![/URL]
Please join our campaign and help support this trial and advance new treatments for MS patients. To make a gift of securities or a fund transfer, contact one of our professional Major Gift Officers at (408) 871-2410. Virginia, Gary, Helen or Patrick would be happy to help you with your contribution.
You can also help by forwarding this email to your friends, co-workers and family members.
All my best,
[IMG]http://ih.constantcontact.com/fs120/101 ... mg/285.png[/IMG]
Virginia Saifer
Chief Development Officer
Myelin Repair Foundation
[/QUOTE]
-
Robbie
Net binnen
Net binnen
Van mrf
[QUOTE]Dear Robert,
Our year starts out with a powerful new beginning, an exciting achievement that marks another major milestone for the Myelin Repair Foundation: a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH). The MRF signed a Collaborative Research and Development Agreement or CRADA with NINDS to advance one of MRF's potential compounds into clinical development.
This compound--which we will refer to as MRF-008--is a generic drug our academic research consortium has identified as a potential candidate to protect and repair myelin in MS patients. Since MRF-008 is already FDA-approved for another disease indication, the MRF and the NIH see a tremendous opportunity to investigate the repurposing of this drug to protect and repair myelin in multiple sclerosis patients. Utilizing our Accelerated Research Collaboration™ (ARC) model, the MRF accelerated the advancement of MRF-008 from basic research through the translational gap, into clinical development. Joining forces with clinicians from the National Institute for Neurological Disorders and Stroke, we will devise an innovative clinical development strategy to investigate MRF-008 for MS patients.
Our partnership with the NIH will advance the clinical development of MRF-008, while addressing our overarching goal to satisfy unmet medical needs for patients with MS. We cannot disclose the name of the MRF-008 therapeutic yet, but we look forward to sharing exciting updates about this potential opportunity.
This milestone is a testament to the strength and efficiency of our ARC model, aimed at bridging all the steps in the therapeutic development process--from initial research all the way to the clinic--toward achieving our goal of delivering the first myelin repair treatment for MS in 2019. With the MRF's world-class advisors, academic scientists and research staff, we have created a powerful dream team to build upon our tremendous research momentum to achieve even greater milestones in 2014.
Our pipeline includes other potential MS therapeutics that can be expedited through our Translational Medicine Platform into the clinic, only with your valuable support. Every day, we are laser-focused on accelerating effective therapeutics forward to MS patients. On behalf of all of us at the Myelin Repair Foundation, thank you for all of your support. We invite you to join us on our impassioned quest to create a healthier future for MS patients.
Sincerely,
Scott Johnson
President, CEO and Founder
Myelin Repair Foundation[/QUOTE]
Van mrf
[QUOTE]Dear Robert,
Our year starts out with a powerful new beginning, an exciting achievement that marks another major milestone for the Myelin Repair Foundation: a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH). The MRF signed a Collaborative Research and Development Agreement or CRADA with NINDS to advance one of MRF's potential compounds into clinical development.
This compound--which we will refer to as MRF-008--is a generic drug our academic research consortium has identified as a potential candidate to protect and repair myelin in MS patients. Since MRF-008 is already FDA-approved for another disease indication, the MRF and the NIH see a tremendous opportunity to investigate the repurposing of this drug to protect and repair myelin in multiple sclerosis patients. Utilizing our Accelerated Research Collaboration™ (ARC) model, the MRF accelerated the advancement of MRF-008 from basic research through the translational gap, into clinical development. Joining forces with clinicians from the National Institute for Neurological Disorders and Stroke, we will devise an innovative clinical development strategy to investigate MRF-008 for MS patients.
Our partnership with the NIH will advance the clinical development of MRF-008, while addressing our overarching goal to satisfy unmet medical needs for patients with MS. We cannot disclose the name of the MRF-008 therapeutic yet, but we look forward to sharing exciting updates about this potential opportunity.
This milestone is a testament to the strength and efficiency of our ARC model, aimed at bridging all the steps in the therapeutic development process--from initial research all the way to the clinic--toward achieving our goal of delivering the first myelin repair treatment for MS in 2019. With the MRF's world-class advisors, academic scientists and research staff, we have created a powerful dream team to build upon our tremendous research momentum to achieve even greater milestones in 2014.
Our pipeline includes other potential MS therapeutics that can be expedited through our Translational Medicine Platform into the clinic, only with your valuable support. Every day, we are laser-focused on accelerating effective therapeutics forward to MS patients. On behalf of all of us at the Myelin Repair Foundation, thank you for all of your support. We invite you to join us on our impassioned quest to create a healthier future for MS patients.
Sincerely,
Scott Johnson
President, CEO and Founder
Myelin Repair Foundation[/QUOTE]